Trials / Completed
CompletedNCT04064034
ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer
Evaluation of the Diagnostic Potential a Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Accepted
Summary
Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancreas cancer and subjects without pancreas cancer to see if this test could be used to diagnosis pancreas cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Lateral Flow Assay (LFA) | Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein |
Timeline
- Start date
- 2019-08-01
- Primary completion
- 2020-10-31
- Completion
- 2020-10-31
- First posted
- 2019-08-21
- Last updated
- 2020-12-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04064034. Inclusion in this directory is not an endorsement.